MTA1: Metastasis-associated 1 Gene and Its Functions in Cancer Development

Target Name: MTA1

NCBI ID: G9112

MTA1

MTA1: Metastasis-associated 1 Gene and Its Functions in Cancer Development

Metastasis-associated 1 (MTA1), also known as transcript variant 1, is a protein that is expressed in various tissues and has been implicated in the regulation of cancer cell growth, metastasis and angiogenesis. The MTA1 gene has been implicated in the development and Progression of many types of cancer, including breast, lung, and colorectal cancer.

One of the key functions of MTA1 is its role in cell signaling pathways, particularly in the regulation of cell growth and the control of cell division. MTA1 has been shown to play a role in the regulation of cell cycle progression, and has been shown to interact with several different signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway.

In addition to its role in cell signaling pathways, MTA1 has also been shown to be involved in the regulation of cellular processes that are critical for the development of cancer. For example, MTA1 has been shown to play a role in the regulation of angiogenesis, the process by which new blood vessels are formed in the body, and has been shown to be involved in the development of cancer-derived angiogenesis.

MTA1 has also been shown to be involved in the regulation of stem cell maintenance and proliferation. MTA1 has been shown to play a role in the regulation of stem cell self-renewal and has been shown to be involved in the development of cancer stem cells.

In conclusion, MTA1 is a protein that has been shown to play a critical role in the regulation of cell signaling pathways, cellular processes that are critical for the development of cancer and the regulation of stem cell maintenance and proliferation. As a potential drug target, MTA1 is a promising target for the development of new cancer therapies.

Protein Name: Metastasis Associated 1

Functions: Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator (PubMed:16617102, PubMed:17671180, PubMed:17922032, PubMed:21965678, PubMed:24413532). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). In the NuRD complex, regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA (PubMed:17671180). In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A (PubMed:17922032, PubMed:24413532). Acts as a transcriptional coactivator of BCAS3, and SUMO2, independent of the NuRD complex (PubMed:21965678, PubMed:17671180, PubMed:16617102). Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3 (By similarity). Regulates p53-dependent and -independent DNA repair processes following genotoxic stress (PubMed:19837670). Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair (PubMed:19837670). Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles (By similarity). Positively regulates the CLOCK-BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1 (By similarity). Regulates deacetylation of BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression (By similarity). With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation (By similarity)

The "MTA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets